Dianthus Therapeutics, Inc.
DNTH
$115.96
$6.365.80%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -58.76% | -38.37% | -126.55% | -46.04% | -79.64% |
| Total Depreciation and Amortization | 8.08% | -42.86% | 24.36% | -14.66% | -10.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 33.86% | 183.96% | 263.43% | 173.15% | 71.18% |
| Change in Net Operating Assets | -264.22% | 233.25% | 3,057.82% | 9.85% | 956.06% |
| Cash from Operations | -105.01% | -4.44% | -71.20% | -43.67% | -64.45% |
| Capital Expenditure | -293.48% | 58.33% | -345.16% | 80.00% | -170.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,905.65% | -1,004.06% | 261.80% | 22.39% | 2,133.64% |
| Cash from Investing | -1,909.48% | -1,005.59% | 260.98% | 22.40% | 2,162.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,762.85% | 459,995.03% | -87.21% | 92,698.99% | 1,108.51% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,727.46% | 459,160.87% | -87.69% | 92,640.88% | 125.87% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16,668.98% | 4,648.96% | 54.98% | 115.23% | 120.06% |